McSweeney / Langevin Providing Legal Advice in Response to Alleged Link Between Cholesterol-Lowering Drugs Lipitor, Zocor, Crestor and Type 2 Diabetes in Women

The law firm McSweeney / Langevin is investigating Type 2 Diabetes claims allegedly caused by the cholesterol-lowering drugs Lipitor, Zocor, and Crestor. McSweeney / Langevin's legal investigation follows the Food and Drug Administration's recent warning concerning the link between Lipitor, Crestor and Zocor and a Type 2 Diabetes diagnosis in postmenopausal women.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
We have dedicated a tremendous amount of resources to statin-related claims due to the extraordinary injuries woman have allegedly sustained from Lipitor, Crestor, Zocor and other drugs in its class

(PRWEB) October 11, 2013

The law firm McSweeney / Langevin is reviewing potential claims against the manufacturers of the cholesterol-lowering drugs Lipitor, Zocor and Crestor because of an alleged link between the drugs and Type 2 diabetes in postmenopausal women.

The alleged link follows a study published in the Journal of American Medical Association which discovered women between the ages of 50 and 79 who took statin medicines such as Lipitor were 48% more likely to develop type 2 diabetes than women who did not.

Shortly after the JAMA study was published, The United States Food and Drug Administration released a Drug Safety Communication regarding important safety label changes to cholesterol-lowering statin drugs. According to the FDA, these cholesterol-lowing drugs are intended to help lower a person’s “bad” cholesterol (low-density lipoprotein cholesterol). The products include: Lipitor (atorvastatin), Lescol (fluvastatin), Mevacor (lovastatin), Altoprev (lovastatin extended-release), Livalo (pitavastatin), Pravachol (pravastatin), Crestor (rosuvastatin), and Zocor (simvastatin). Combination products include: Advicor (lovastatin/niacin extended-release), Simcor (simvastatin/niacin extended-release), and Vytorin (simvastatin/ezetimibe). These cholesterol-lowering drugs belong to a family of drugs known as statins.

The FDA warned that diabetes occurs because of defects in the body’s ability to produce or use insulin—a hormone needed to convert food into energy. If the pancreas doesn't make enough insulin or if cells do not respond appropriately to insulin, blood sugar levels in the blood get too high, which can lead to serious health problems.

A small increased risk of raised blood sugar levels and the development of Type 2 diabetes have been reported with the use of statins.

As a result of this new warning, McSweeney / Langevin has begun to investigate potential cholesterol-lowering drug claims involving postmenopausal woman who are suffering from Type 2 diabetes following statin use.

“We have dedicated a tremendous amount of resources to statin-related claims due to the extraordinary injuries woman have allegedly sustained from Lipitor, Crestor, Zocor and other drugs in its class,” said Rhett McSweeney, founding partner of McSweeney / Langevin. “We are providing free legal consultations to people suffering from injuries due to statins in an effort to provide a resolution to the damage that has been done.”

About McSweeney / Langevin

With the sole purpose of helping the injured, the personal injury law firm McSweeney / Langevin ensures victims and victims’ families are adequately compensated for wage loss, medical expenses and pain and suffering. While most firms have you speak with an “investigator” or “case manager,” McSweeney / Langevin connects people directly with one if its attorneys who will be handling your case. The firm handles personal injury cases related to dangerous/defective pharmaceutical drugs, dangerous/defective medical devices, and serious/catastrophic injury claims. For more information, visit http://www.westrikeback.com or call 1-800-888-4425.